Approximate Entropy of the Placebo Effect in Clinical Trials with New Generation Antidepressants
DOI:
https://doi.org/10.31053/1853.0605.v67.n4.22566Keywords:
depresión, antidepresivo, placebo, entropía aproximadaAbstract
Recent research concluded that antidepressant drugs are ineffective in treating moderate or severe depression. Statistically, there are no differences between the results with active drugs or placebo. Some authors have attributed this fail to variability or irregularity of the placebo effect in depressed patients or artifacts induced by meta-analysis.
This fact highlights the difficulties faced by the research of psychoactive drugs in depression and revives the debate about the usefulness of the employ of placebo in these studies. This study aimed to determine the variability of the placebo effect in antidepressant clinical trials in simple linear and nonlinear complex models. We performed a secondary analysis of data from 35 trials presented as evidence to the Food and Drug Administration (FDA) for approval of new generation antidepressants, all double-blind controlled with placebo in patients with unipolar mild or moderate depressive disorder, according to the criteria of "Diagnostic and Statistical Manual of Mental Disorders (DSM).Articles reviewed included 5133 patients . We have calculated the coefficient of variability, autocorrelation and approximate entropy of the placebo and treatment effects to determine whether the variability or regularity between different studies should be attributed to meta-analytical methods, placebo effect or ineffective treatment itself. The coefficient of variability in the placebo group was 26.49% and 18.81% in the treatment group. The placebo effect autocorrelation was within the confidential limits while the treatment group was outside showed cyclical variation. The approximate entropy value (ApEn N=35,m=2,R=2) in the placebo group was 0.5579 and 0.5744 in treatment group, leading to the conclusion that placebo effect is highly consistent and regular in complex non-linear models. The apparent variability of the placebo effect in depressed patients slould be due to artifacts induced by simple linear models analysis.
Downloads
References
Straus JL von Ammon, Cavanaught S. Placebo effects. Issues for clinical practice in psychiatry and medicine. Psychosomatics 1996; 37: 315-326.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Jonson BT. Initial severity and antidepressants benefits: Ameta-analysis of data submitted to the Food and Drug Administration. PloS Med 2008; 5: e45.
Andrews G. Placebo response in depression: bane of research, boon to therapy (Editorial). Br J Psychiatry 2001; 178: 192-194.
Kendler KS, Walters EE, Kessler RC. The prediction of length of major depression episodes: results from an epidemiological survey of female twins. Psychological Medicine 1997; 27: 107-117.
Andrews G. Placebo response in depression: bane of research, boon to therapy (Editorial). Br J Psychiatry 2001; 178: 192-194.
Thase ME. Remission is the optimal goal of acute phase antidepressant therapy. Actas Esp Psiquiatr 2008; 36(Suppl 1): 7-16.
Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments of antidepressants and placebo response rates in antidepressant efficacy trials. Metaanalysis. Br J Psychiatry 2007; 190: 287-292. 8. Brown WA, Khan A. Which depressed patients should receive antidepressants? CNS Drugs 1994; 5: 341-347.
Bialik RJ, Ravindan AV, Bakish D, Lapierre YD. A comparison of placebo responders and non responders in subgroups of depressive disorders. J Psychiatry Neurosci 1995; 20: 265-270.
Khan A, Brown WA. The placebo enigma in antidepressant clinical trials. J Clin Psychopharmacol 2001; 21: 123-125.
Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001; 15: 765-776.
Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55: 334-343.
Ranga RK. Efficient trial design to reduces placebo requirement. Biol Psychiatry 2000; 47: 724-726.
Lolas F. Depresión y efecto placebo: un tema de investigación bioética. Monografías de Psiquiatría 2003; 15(3): 17-20.
Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 2008; 59: 565-590.
Leuchter AF, Cook IA,Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002; 159: 122-129.
Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737.
Benedetti F, Mayberg HS, Wager TD, Stholer CS, Zubieta JK. Neurobiological Mechanisms of the placebo effect. J Neurosci 2005; 25: 10390-10402.
Cuestas E. [Complex systems variability analysis using approximate entropy.]. Rev Fac Cien Med Univ Nac Cordoba. 2010 Jun;67(1):77-80.
Thase ME. How should efficacy be evaluated in randomized clinicals trials of treatment for depression? J Clin Psychiatry 1999; 60(Suppl 4): 23-31.
Trivedi MH, Rush H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressants medications? Neuropsychopharmacology 1994; 11: 33-43.
Keck PE, Welge JA, McElroy SL, Arnold LM, Strakowski LM. Placebo effect in randomized, controlled studies of acute bipolar mania and depression. Biol Psychiatry 2000; 47: 748-755.
Richman JS, Moorman JR. Physiological time-series analysis using approximate entropy and sample entropy. Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H2039-49. PubMed PMID: 10843903.
Downloads
Published
Issue
Section
License
Copyright (c) 2010 Universidad Nacional de Córdoba
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The generation of derivative works is allowed as long as it is not done for commercial purposes. The original work may not be used for commercial purposes.
How to Cite
